Premium Nahrungsergänzungsmittel | artgerecht

Antifibrotic – Meaning, Agents and Therapy

Antifibrotic refers to substances or therapies that counteract the pathological formation of excess connective tissue (fibrosis). They are used in conditions such as liver cirrhosis or pulmonary fibrosis.

Regular tips about health Regular tips about health

Things worth knowing about "Antifibrotic"

Antifibrotic refers to substances or therapies that counteract the pathological formation of excess connective tissue (fibrosis). They are used in conditions such as liver cirrhosis or pulmonary fibrosis.

What Does Antifibrotic Mean?

Antifibrotic is a medical term describing agents, therapies, or biological mechanisms that inhibit or reverse the excessive accumulation of connective tissue, a process known as fibrosis. Fibrosis occurs when the body deposits too much collagen and scar tissue, impairing normal organ function.

What Is Fibrosis?

Fibrosis is the pathological overgrowth of connective tissue in response to chronic inflammation, injury, or toxic damage. It can affect virtually any organ, but the most commonly involved include:

Liver (liver fibrosis, liver cirrhosis)
Lungs (idiopathic pulmonary fibrosis, IPF)
Kidneys (renal fibrosis)
Heart (cardiac fibrosis)
Skin (e.g., in systemic sclerosis)

Left untreated, fibrosis can lead to complete loss of organ function.

Mechanism of Action of Antifibrotic Therapies

Antifibrotic substances intervene at multiple stages of the fibrotic process. A central focus is the inhibition of signaling molecules that promote the formation of scar tissue.

Key Therapeutic Targets

TGF-beta (Transforming Growth Factor Beta): One of the most important profibrotic cytokines; its inhibition reduces collagen production.
Activated stellate cells and myofibroblasts: These cells are primarily responsible for collagen deposition; antifibrotic compounds can block their activation.
Anti-inflammatory action: Since chronic inflammation is a central driver of fibrosis, many antifibrotic agents also exert anti-inflammatory effects.
Matrix metalloproteinases (MMPs): Enzymes that can promote the breakdown of excess connective tissue.

Antifibrotic Compounds and Medications

Several antifibrotic drugs are already approved for clinical use, while many more are under active investigation:

Approved Agents

Pirfenidone: Approved for the treatment of idiopathic pulmonary fibrosis (IPF); inhibits TGF-beta and other growth factors.
Nintedanib: A tyrosine kinase inhibitor also used in IPF and systemic sclerosis; blocks growth factor receptors that drive fibrotic processes.

Compounds Under Research

Galectin-3 inhibitors
LOXL2 inhibitors (lysyl oxidase-like 2 inhibitors)
RAAS inhibitors (e.g., ACE inhibitors, ARBs) for renal and cardiac fibrosis
Natural compounds such as curcumin and resveratrol, which have shown antifibrotic effects in preclinical and early clinical studies

Clinical Application

Antifibrotic therapies are used to slow or halt disease progression in chronic organ diseases. The goal is not always to fully reverse established fibrosis – which is often only partially possible – but to prevent further progression and preserve organ function for as long as possible.

Treatment is always administered under medical supervision, as antifibrotic medications can cause side effects, including:

Nausea and gastrointestinal complaints (particularly with pirfenidone)
Elevated liver enzyme levels
Increased sensitivity of the skin to sunlight

Significance in Modern Medicine

Antifibrotic research is one of the most rapidly expanding fields in medicine. Since fibrosis represents a common final pathway of many chronic diseases – from diabetes to viral hepatitis – the development of effective antifibrotic strategies holds enormous therapeutic potential for millions of patients worldwide.

References

Wynn, T. A. & Ramalingam, T. R. (2012): Mechanisms of fibrosis: therapeutic translation for fibrotic disease. In: Nature Medicine, 18(7), 1028–1040. https://doi.org/10.1038/nm.2807
Richeldi, L. et al. (2014): Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. In: New England Journal of Medicine, 370(22), 2071–2082.
European Medicines Agency (EMA): Product information for Esbriet (pirfenidone) and Ofev (nintedanib). https://www.ema.europa.eu

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.